Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:2:p9
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 2 (pt 9/16)
Character Range: 141882–144696

preparations containing 0.3% or less of hydroquinone; or
 (b) in cosmetic nail preparations containing 0.02% or less of hydroquinone.
HYOSCINE:
 (a) for transdermal use in preparations containing 2 mg or less of total solanaceous alkaloids per dosage unit; or
 (b) for oral use:

          (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

          (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids.
HYOSCINE BUTYLBROMIDE as the only therapeutically active substance, in divided preparations for oral use, containing 20 mg or less of hyoscine butylbromide per dosage unit in a pack containing 200 mg or less of hyoscine butylbromide.
HYOSCYAMINE:
 (a) for external use in preparations containing 0.03% or less of total solanaceous alkaloids; or
 (b) for oral use:

          (i) in undivided preparations containing 0.03% or less of total solanaceous alkaloids, when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or

          (ii) in divided preparations containing 0.3 mg or less of total solanaceous alkaloids per dosage unit when labelled with a recommended daily dose of 1.2 mg or less total solanaceous alkaloids.
HYOSCYAMUS NIGER for oral use:
 (a) in undivided preparations containing 0.03% or less of total solanaceous alkaloids when labelled with a dose of 0.3 mg or less of total solanaceous alkaloids and a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids; or
 (b) in divided preparations containing 0.3 mg of total solanaceous alkaloids or less per dosage unit when labelled with a recommended daily dose of 1.2 mg or less of total solanaceous alkaloids;
 except in a pack containing 0.03 mg or less of total solanaceous alkaloids.
IBUPROFEN in preparations for oral use that are labelled with a recommended daily dose of 1200 mg or less of ibuprofen, when:
 (a) in liquid preparations that are sold in the manufacturer's original pack containing 8 g or less of ibuprofen; or
 (b) in divided immediate release preparations:

          (i) each containing 400 mg or less of ibuprofen in a primary pack containing not more than 12 dosage units; and

 (ii) that are labelled not for the treatment of children under 12 years; or
 (c) in divided preparations, each containing 200 mg or less of ibuprofen, in packs of not more than 100 dosage units except when:

          (i) ibuprofen is the only therapeutically active constituent, other